AXIS Clinicals US Patient trials Expansion: Oncology, Ophthalmology, Dermatology
AXIS Clinicals, a CRO offering clinical pharmacology services addressing needs of the evolving clinical research industry, and our clients, AXIS Clinicals has established as an extension of our organization the following therapeutic experts to advance our services bringing targeted patients into trials earlier within the drug development process.
In addition to performing First-in-Human, Single Ascending Dose/Multiple Ascending dose pharmacology projects, AXIS can offer patient overnight confinement at our Minnesota CPU to support Phase Ia/2b studies. Sequentially we offer multi-center Phase 2/3 trials within oncology, ophthalmology, and dermatology drug development announcing the appointments of:
Dr. Sai Chavala:
Dr. Chavala is a clinician-surgeon-scientist, dedicated to innovation and development of novel treatments that improve the quality of life of patients. After obtaining his MD, he completed residency/fellowship at Weill Medical College of Cornell University and Duke University. His research has been funded by NIH. He is a Professor of Surgery at TCU/UNTHSC School of Medicine in Fort Worth.
Dr. Michael J. Blankinship:
ima board-certified dermatologist. Dr. Blankinship provides comprehensive care to patients with various types of skin conditions and diseases. He lives in Fargo with his wife, Sunny and their three children. He and his family enjoy traveling and spending time at their lake cabin. He is originally from the Upper Peninsula of Michigan and enjoys hunting and fishing. He was a Big Ten bass fishing champion in 1999.
Dr. Erard M. Gilles:
20 years’ experience in the pharmaceutical industry covering: R&D experience in large and small companies, creation and development of Invivis Pharmaceuticals Inc., Medical Affairs and Marketing
“I am excited for the growth of our clinic to be able to support overnight confinement for patient populations. We have a strong history of performing complex healthy volunteer studies, and feel we are ideally positioned to support the research needs for Phase 1a/2b studies.”, said Dr. Pete Boldingh, the Vice President of Clinical Operations at AXIS Clinicals USA.
For further information, please feel free to contact John Pottier, Senior Vice President Business Development 913-314-6755 j.pottier@axisclinicals.com